PMA device
Ocucoat (2% Hydroxpropylmethylcellulose Solution)
Bausch & Lomb, Inc. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Dec 21, 2006, newest May 4, 2012Cataract
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
53
Naming "Ocucoat"
MAUDE reports
0
Brand "Ocucoat", since 2015
PubMed studies
18
Mentioning "Ocucoat"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ocucoat (2% Hydroxpropylmethylcellulose Solution)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 3 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Ocucoat", any status and sponsor, newest update first.
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT06190054 · 100 participants · Start Feb 6, 2023 · Primary completion Jan 3, 2025
Device: MERAMIRT · For: Dry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal Users
Sites: Piario, Italy; Roma, Italy; Salerno, Italy · 4 sites in all
- Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract SurgeryNot yet recruiting
Medical University of ViennaAcademic, hospital or other
NCT07809022 · 25 participants (planned) · Start Sep 15, 2026 · Primary completion Oct 1, 2027
Device: LACRIFILL® Canalicular Gel administration · For: Dry Eye; Dry Eye Disease (DED); Dry Eye Sensation After Cataract Surgery
Sites: Vienna, Austria
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGDPivotal-lookingCompleted
Chinese University of Hong KongAcademic, hospital or other
NCT05577910 · 374 participants · Start Oct 8, 2022 · Primary completion Dec 1, 2024
Device: Vectored thermal pulsation (VTP) therapy; Intense pulsed light with meibomian gland expression (IPL+MGX) therapy · For: Meibomian Gland Dysfunction
Sites: Kowloon, Hong Kong; Shatin, Hong Kong · 4 sites in all
50 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ocucoat", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LZP
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Ocucoat"[tiab]. The summary above synthesizes these.
- Intraocular pressure rise after small incision cataract surgery: a randomised intraindividual comparison of two dispersive viscoelastic agents.
Rainer G, Menapace R, Findl O, et al. · Br J Ophthalmol · 2001Clinical Trial, Comparative Study
- Endotoxins in ophthalmic viscosurgical devices.
Dick HB, Augustin AJ, Pakula T, et al. · Eur J Ophthalmol · 2003Comparative Study
- Corneal thickness and visual acuity after phacoemulsification with 3 viscoelastic materials.
Davis EA, Lindstrom RL · J Cataract Refract Surg · 2000Clinical Trial, Comparative Study
- Corneal endothelial cell protection with a dispersive viscoelastic material and an irrigating solution during phacoemulsification: low-cost versus expensive combination.
Kiss B, Findl O, Menapace R, et al. · J Cataract Refract Surg · 2003Clinical Trial, Comparative Study
- Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery.
Malvankar-Mehta MS, Fu A, Subramanian Y, et al. · J Ophthalmol · 2020Review
- The potential calcification of octacalcium phosphate on intraocular lens surfaces.
Guan X, Tang R, Nancollas GH · J Biomed Mater Res A · 2004Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Physical Characteristics, Clinical Application, and Side Effects of Viscoelastics in Ophthalmology.
Mohammadpour M, Asadigandomani H, Aminizade M, et al. · J Curr Ophthalmol · 2023Review
- Evaluation of intraocular pressure in the immediate postoperative period after phacoemulsification.
Shingleton BJ, Rosenberg RB, Teixeira R, et al. · J Cataract Refract Surg · 2007Research Support, Non-U.S. Gov't
- Comparison of the effect of Healon, Healon GV, Healon 5, Viscoat, and Ocucoat on platelet aggregation under in vitro conditions.
Aras C, Baslar Z, Unal M, et al. · Eur J Ophthalmol · 2006Comparative Study
- [Classification of visco-elastic substances for ophthalmologic surgery].
Dick B, Schwenn O, Pfeiffer N · Ophthalmologe · 1999Comparative Study, English Abstract
- Efficacy of hyaluronidase in reducing increases in intraocular pressure related to the use of viscoelastic substances.
Harooni M, Freilich JM, Abelson M, et al. · Arch Ophthalmol · 1998Comparative Study, Research Support, U.S. Gov't, P.H.S.
- Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery.
Holzer MP, Tetz MR, Auffarth GU, et al. · J Cataract Refract Surg · 2001Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)Johnson & Johnson Surgical Vision, Inc. · PMA 2024
- Amvisc & Amvisc Plus OvdBausch & Lomb, Inc. · PMA 2017
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Biolon (1% Sodium Hyaluronate for Ophthalmic Surgery)Altacor , Ltd. · PMA 2005
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.